Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director

Oncocyte Corp (OCX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 8-K/A Quarterly results
10/05/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS"
07/24/2023 8-K Quarterly results
07/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT , is entered into effective July 13, 2023 by and between Oncocyte Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs . WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, effective May 1, 2023 ; WHEREAS, pursuant to Section 12 of the Employment Agreement, the Employment Agreement may be amended, in writing, signed by both the Company and Executive; WHEREAS, the Company and Executive desire to amend the Employment Agreement as set forth herein; and WHEREAS, capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Employment Agreement. NOW, THEREFORE, in ..."
07/10/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/30/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/15/2023 4 KINGSLEY ALFRED D (Director) has filed a Form 4 on Oncocyte Corp
Txns: Bought 30,000 shares @ $0.2149, valued at $6.4k
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT is entered into as of June 6, 2023, by and between Oncocyte, Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs ."
06/06/2023 8-K Investor presentation
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/11/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/13/2023 8-K Quarterly results
04/05/2023 4 BROADWOOD PARTNERS, L.P. (10% Owner) has filed a Form 4 on Oncocyte Corp
Txns: Bought 26,827,638 shares @ $0.3017, valued at $8.1M
04/05/2023 4 Gutfreund John Peter (Director) has filed a Form 4 on Oncocyte Corp
Txns: Granted 705,000 shares @ $0.3544, valued at $249.9k
Granted 1,000,000 shares @ $0.3544, valued at $354.4k
Disposed/sold 588 convertible preferred @ $0
04/05/2023 4 Arno Andrew (Director) has filed a Form 4 on Oncocyte Corp
Txns: Granted 141,084 shares @ $0.3544, valued at $50k
Granted 141,084 shares @ $0.3544, valued at $50k
Granted 141,084 shares @ $0.3544, valued at $50k
04/05/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/05/2023 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
03/31/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ONCOCYTE REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS"
03/08/2023 4 PURA VIDA INVESTMENTS, LLC (10% Owner) has filed a Form 4 on Oncocyte Corp
Txns: Disposed of 3,890,111 shares @ $0
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer"
02/28/2023 4 Riggs Josh (CEO) has filed a Form 4 on Oncocyte Corp
Txns: Granted 116,426 options to buy @ $0.39, valued at $45.4k
02/28/2023 4 John Anish M. (CFO) has filed a Form 4 on Oncocyte Corp
Txns: Granted 121,381 options to buy @ $0.39, valued at $47.3k
02/23/2023 8-K Asset disposition
Docs: "Second AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT is adopted as of the 16th day of February, 2023 , by and among Oncocyte Corporation, a California corporation , Dragon Scientific, LLC, a Delaware limited liability company , and Razor Genomics, Inc., a Delaware corporation . Seller, Company, and Buyer are referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement . WHEREAS, Buyer, Seller and the Company have entered into that certain Stock Purchase Agreement, dated as of December 15, 2022 and amended the same pursuant to that certain First Amendment to Stock Purchase Agreement entered into as...",
"ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 16, 2023, Oncocyte Corporation completed its sale of 3,188,181 shares of common stock of its wholly-owned subsidiary Razor Genomics, Inc. , which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, pursuant to a previously announced Stock Purchase Agreement with Dragon Scientific, LLC, a Delaware limited liability company , and Razor, a Delaware corporation . In connection with the Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx TM , a test used to predict a patient’ s risk of cancer recurrence following surgery and response to chemotherapy in early-stage lung cancer. Following the Closing...",
"ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy